NVCRNovoCure Ltd.Finished
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
8 insiders sold shares within a month
Since Jun 4, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 84 (final count)
- Started
- Aug 21, 2023
- Main results expected
- Nov 18, 2025
- Fully finished
- Nov 18, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Disease control rate (DCR)
Measured over: at least 16 weeks for SD or confirmed PR/CR
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.7, since 2026-06-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06390059 · record last updated 2026-09-04 · checked 2026-11-09 15:47 UTC